The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•23 March 2026•

1 min read

Jefferies Resumes Oxford BioMedica Coverage with Buy Rating and 41% Upside Potential

Key Facts

1Jefferies resumed coverage of Oxford BioMedica with a 'buy' rating and a price target of £8.27.

2The price target implies a 41% upside from the current share price of £5.88.

Jefferies has resumed its coverage of Oxford BioMedica PLC with a "buy" rating, setting an ambitious price target of £8.27. This new target suggests a significant 41% upside potential compared to the current share price of £5.88. The investment bank also raised its medium-term earnings estimates for the company by 4%, citing a strategic manufacturing agreement with Bristol Myers Squibb (BMY). Analysts believe this partnership significantly de-risks the company's operations and strengthens its path toward sustainable profitability. The move reflects growing confidence in Oxford BioMedica's specialized role within the biotechnology and pharmaceutical sectors. This positive analyst sentiment is expected to drive increased investor interest in the London-listed equity.